Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 9, 2013, Pages 3501-3506

  Edris, Badreddin ^a   Willingham, Stephen B ^a   Weiskopf, Kipp ^a   Volkmer, Anne K ^a,b   Volkmer, Jens Peter ^a   Mühlenberg, Thomas ^c   Montgomery, Kelli D ^a   Contreras Trujillo, Humberto ^a   Czechowicz, Agnieszka ^a   Fletcher, Jonathan A ^d   West, Robert B ^a   Weissman, Irving L ^a   Van De Rijn, Matt ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Gleevec; Immunotherapy; Leiomyosarcoma

Indexed keywords

BORTEZOMIB; IMATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SR1; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; MACROPHAGE; MISSENSE MUTATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHAGOCYTOSIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874471799     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222893110     Document Type: Article

References (28)

1. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer 11(12): 865-878.
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152(5): 1259-1269.
3. Yuzawa S, et al. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130(2): 323-334.
4. Hirota S, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350): 577-580.
5. Heinrich MC, et al. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3): 925-932.
6. Tuveson DA, et al. (2001) STI571 inactivation of the gastrointestinal stromal tumor c- KIT oncoprotein: Biological and clinical implications. Oncogene 20(36): 5054-5058.
7. Mol CD, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c- Kit tyrosine kinase. J Biol Chem 279(30): 31655-31663.
8. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 33(5): 466-477.
9. Broudy VC, et al. (1992) Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood 79(2): 338-346.
10. Ashman LK, Bühring HJ, Aylett GW, Broudy VC, Müller C (1994) Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1. J Cell Physiol 158(3): 545-554.
11. Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66(18): 9153-9161.
12. Bühring HJ, et al. (1993) Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia. Cancer Res 53(18): 4424-4431.
13. Fang HT, et al. (2012) Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci USA 109(7): 2521-2526.
14. Ito M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood 100(9): 3175-3182.
15. West RB, et al. (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165(1): 107-113.
16. Espinosa I, et al. (2008) A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32(2): 210-218.
17. Matsumoto K, et al. (2011) Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 41(1): 57-62.
18. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5): 317-327.
19. Esposito I, et al. (2002) The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 82(11): 1481-1492.
20. Kemmer K, et al. (2004) KIT mutations are common in testicular seminomas. Am J Pathol 164(1): 305-313.
21. Woodman SE, Davies MA (2010) Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5): 568-574.
22. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC; The Children's Cancer Group (1994) Expression of stem cell factor and c-kit in human neuroblastoma. Blood 84(10): 3465-3472.
23. Johansson I, et al. (2012) Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer 51(4): 375-383.
24. Edris B, et al. (2012) ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 227(2): 223-233.
25. Mühlenberg T, et al. (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69(17): 6941-6950.
26. Ueno H, Weissman IL (2006) Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. Dev Cell 11(4): 519-533.
27. Edris B, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109(17): 6656-6661.
28. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109 (17): 6662-6667.